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Interventional treatment of patients with
stroke should rekindle a push for ‘persona-
lised’ medicine. In 1988, more than a
quarter of a century ago, one of us (LRC)
made a plea for personalised care in an edi-
torial ‘What is wrong with Mr. Jones’.1 At that
time, the technological tools available to
image the brain and its vascular supply were
far inferior to those available now. That edi-
torial was focused on patients with transient
ischaemic attacks (TIAs). Now experience
has accrued concerning detailed persona-
lised clinical and technological evaluation of
patients with brain ischaemia and haemor-
rhage evaluated urgently and even those who
have less urgent presentations seen in out-
patient settings. Recent focus has centred on
rapid management of patients with acute
stroke. Randomised trials have now shown
the effectiveness of aggressive interventional
endovascular treatment of patients with
ischaemic stroke diagnosed using modern
brain and vascular imaging technology.2–7
Much has been written about these recent
randomised trials of interventional treatment
of selected individuals who have acute brain
ischaemia. These studies proved that patients
carefully selected using advanced brain and
vascular imaging had better outcomes by
applying interventional techniques that
opened occluded brain-supplying arteries
than controls primarily treated only with
standard intravenous thrombolysis.2–7 The
discussions and editorials8 9 that followed
publication and presentations of the results
of these trials have understandably mostly
consisted of analyses that answer very prac-
tical questions. What is the time frame in
which the treatment is likely to succeed?
How is success measured? Which patients
with what vascular lesions and what volume
of brain infarction should be treated? Does
the amount of collateral circulation already
mobilised matter and, if so, how should it be
measured? Does the ‘clot burden’ shown
before treatment affect the ability to open
the artery or bleeding after clot removal?
What technology should be used to open the
blocked arteries—intra-arterial thrombolytics,
stent retrievers, suction or combinations of
these? What should be the qualiﬁcations and
training of those who perform the interven-
tional clot retrieval therapy?
Other discussions focused on general com-
munity resource issues. Can patients with
acute stroke be treated in the ambulance or
primary stroke centre close to where the
stroke developed? If so, is it economically
and practically feasible to send a ‘stroke
mobile’ equipped with a CT scanner and
blood analysis equipment?8–10 Where should
governmental regulations mandate sending
the patient? To the nearest primary stroke
centre or to specialised advanced stroke
centres equipped with the personnel and
technology to provide rapid intra-arterial
interventions?
However, in this Editorial, we will not focus
on any of these practical issues. We intend to
wax philosophical on and attempt to place
these latest stroke trials into the broad
history of stroke and to argue how these
trials could and should inﬂuence the future
of stroke diagnosis and management. We
also aim to place this history in the context
of stroke care in Asia and in China in par-
ticular. The modern history of stroke is short
and much has evolved during our careers as
trainees and stroke physicians. We emphasise
our own experiences because that is what we
know best and know ﬁrst-hand.
During the ﬁrst half of the 20th century,
therapeutic nihilism reigned supreme. There
were no doctors who specialised in stroke,
few neurologists, and no way to effectively
visualise the brain and its vasculature during
life. There were few treatments and none
were well studied.
Knowledge about stroke advanced during
the 1920’s in France by Charles Foix and his
colleagues11 and in Boston during the 1950–
1975 period by Miller Fisher and his collea-
gues Raymond Adams and Pierson
Richardson.12 The technique was an old one
that had been pursued in understanding
other brain diseases by Charcot and
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colleagues—clinical-pathological analyses. A careful
study of brains at necropsy of patients with ischaemic
stroke showed the usual sites and causes of vascular
occlusions, the nature of various vascular and cardiac
lesions, and the usual accompanying clinical signs. Brain
and subarachnoid haemorrhages were also analysed in
detail. Virchow had emphasised the triad (endothelium,
blood, and blood ﬂow and blood clotting) that must be
understood to uncover the pathophysiology of how the
vascular lesions became clinically active. Laboratory ana-
lyses of the blood and the physiology of blood ﬂow
added to that understanding. LRC was taught and
learned during a stroke fellowship with Dr Fisher in
1969 that clinically and pathologically, no two strokes
and no two stroke patients were exactly the same when
studied in depth.
In the latter part of the 20th century, epidemiological
studies and stroke registries added considerable quanti-
tative information. How frequent were various mechan-
isms of brain ischaemia and haemorrhage? What were
the age distributions of various stroke mechanisms and
vascular lesions? Were there differences according to
sex, race, geographical location, and ﬁnancial and social
status? What were the risk factors that promoted strokes?
How could these risk factors be best controlled to
prevent stroke from happening? Nearly all of these
studies included only Caucasian patients living in the
USA and Europe.
With the advent of CT scanning in the 1970s and MR
scans in the 1980s and beyond, it became possible to
image the brain and its blood supply quickly and safely.
With diffusion-weighted/perfusion-weighted MRI (DWI/
PWI), CT and MR angiography, and CT perfusion
(CTP) imaging, the vascular occlusive lesions and the
ischaemic core and the ischaemic penumbra (poten-
tially salvageable ischaemic tissue and the target of acute
stroke therapy) could be identiﬁed and their extent
approximated. Echocardiography and coronary angiog-
raphy gave considerable information about the heart
and its function and its vascular lesions. Blood contents
and coagulation factors could be analysed quickly and
accurately.
Clinicians could now perform clinical-imaging analyses
of what was wrong, that is, ischaemic lesion location and
extent, with their patients with stroke during life even
during the ﬁrst hours after stroke onset, much as physicians
during preceding decades had done only at necropsy.
More stroke doctors were trained. Units devoted solely to
the care of patients with stroke became very popular in
Europe and spread to the USA.13 However, what was
missing was detailed information about treatment.
Beginning in the 1970s, randomised therapeutic
stroke trials were planned and carried out. Initially,
therapeutic trials were mostly performed in the USA
and Europe but towards the end of the century and
during the ﬁrst quarter of the 21st century there were
many Asian trials; in many multicentre trials, Asian
patients predominated. Trials sought to enroll large
numbers of patients to attain statistically signiﬁcant
results. In order to acquire numbers, the trials that
studied stroke prevention had to lump all patients with
brain ischaemia (eg, TIAs and minor strokes) together.
The results obtained were general and not readily
applied to individual patients with varied risk factors and
speciﬁc stroke mechanisms and ﬁndings. The absence of
modern brain and vascular imaging available during
these early trials limited the application of these results
to individual patients. However, even during the 1990s
and the ﬁrst decade of the present century, intravenous
thrombolytic trials recruited and studied lumped
patients with acute strokes characterised mostly by time
since stroke onset. In the landmark NINDS trial of alte-
plase,14 clinical stroke subtyping was obtained but in the
ECASS-3 study15 that showed that alteplase was effective
in the 3–4.5 h time window this basic information was
not obtained, making it impossible to know if all ischae-
mic stroke subtypes actually beneﬁt when treated during
this later time window. In these early thrombolytic trials,
only a plain head CT scan was performed, primarily to
exclude intracranial haemorrhage, so that there was no
demonstration of a vascular occlusion and the effect of
alteplase on opening previously occluded arteries, so
that the target of thrombolysis could not be evaluated.
The results of these trials are difﬁcult to apply to
patients in whom detailed brain and vascular imaging
deﬁnes the vascular lesions, the regions of brain infarc-
tion and brain ischaemia and the extent of the ischae-
mic core and penumbra.
In contrast to the data required in these older
thrombolytic and stroke prevention trials, the recent
interventional trials required advanced brain and vascu-
lar imaging and blood testing.2–7 This information
guided prognosis and choice of acute treatment.
Knowing the nature of the stroke mechanisms and acute
ﬁndings, along with cardiac and other blood marker
studies, helped select patients most likely to beneﬁt from
acute revascularisation. This approach can be cate-
gorised as the personalised approach to the care of patients
with stroke. In editorials in general medical journals, the
term personalised has been used mostly to apply to
genetic data. However, genetics is just one component of
the information that can be gleaned from and applied
to individuals.
Stroke is a very serious and very expensive condition.
It is the major cause of long-term morbidity.
Rehabilitation is expensive as are years of loss of the
ability to work and to support themselves and their fam-
ilies. Individuals with stroke symptoms should now be
studied in depth using blood, cardiac, and brain and vas-
cular imaging examinations. These can be performed
quickly and safely. These data can be used to tailor acute
treatment and stroke and myocardial infarction preven-
tion strategies for that individual patient. Perhaps in the
future, genetic data can be shown to be of added value.
Patients with an acute neurological deﬁcit suggestive
of a stroke should be taken directly, whenever possible,
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to primary or advanced stroke centres that have the
trained personnel and technology to optimally care for
them. Since many smaller centres receiving patients with
stroke may not have physicians trained in vascular neur-
ology, the availability of such experts via telemedicine
provides a solution to potential expertise gaps. Patients
with subacute symptoms can be taken to centres that
can rapidly evaluate patients with TIAs and strokes.
These centres, manned by experienced and trained
stroke physicians, have been shown to be every effective
for preventing subsequent strokes in the UK and Europe
and should be encouraged in the USA and in Asian
countries.16–18 These centres can evaluate patients thor-
oughly and quickly as outpatients without incurring the
additional expense of hospitalisation. They have access
to modern technology and can select the evaluation
appropriate for each individual patient.
Future randomised therapeutic trials should target
speciﬁc stroke issues in patients who have had a thor-
ough evaluation. In patients with rare or infrequent con-
ditions, databases and registries of treatment and
responses can be useful in helping physicians to choose
treatment for these conditions. The old strategy of
lumping diverse groups has had its utility in times past
but will be of limited use in the future. The availability
of advanced CT and MRI studies as well as newer cardiac
testing such as implantable monitors now allows for a
more precise understanding of the cause of an ischae-
mic stroke and whether an individual patient can
beneﬁt from acute stroke therapy. These data are also
very important in choosing the most effective preventive
treatment of that particular patient. If we are truly to
espouse real ‘personalised medicine’ we need to move
ahead. The guide should be the golden rule. How
would you like yourself or your spouse or your parent to
be managed. By non-experts using recipes from trials
based on large groups of inadequately evaluated indivi-
duals or by highly trained physicians using data from
trials and databases and registries that contain very spe-
ciﬁc and detailed information?
In China and in the rest of Asia, there are additional
challenges to delivering personalised medicine but there
are also advantages. Serving the very large number of
patients (>one billion) in China and their geographic
dispersion with many rural areas that are inadequately
supplied with trained physicians provides the greatest
challenge. There is now a lack of well-trained, experi-
enced neurologists and stroke physicians to care for the
Chinese population. The short times physicians are
given to see individual patients also hampers doctors’
ability to deliver true personalised care.
There are also important opportunities to study stroke
and cerebrovascular disease in China. Results of these
studies can facilitate the delivery of personalised stroke
medicine. The large numbers of patients allow the study
of prespeciﬁed subgroups that will be large enough to
ensure statistical validity. Chinese stroke physicians and
researchers have developed excellent corroborative
arrangements and organisations to plan research and
data accrual. They have already created computerised
registries to acquire large bodies of information. In
China, it should be possible for the government and
organisations of stroke physicians to direct the creation of
stroke centres. Planning for effective delivery of patients
to primary and advanced stroke centres can then begin
and rules can be derived for optimum delivery of patients
to these stroke centres. Personalised care can become a
reality in China, Asia, as well as in the USA and Europe.
However, it will take time and effective planning.
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